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Abstract
Background/purpose: Recently, the mutational background of diffuse large B cell lymphoma (DLBCL) has been
revealed, identifying specific genetic events that drive lymphomagenesis. However, the prognostic value of these
mutations remains to be determined. Prognostic biomarkers in DLBCL are urgently needed, since the current
clinical parameter-based factors (e.g., International Prognostic Index (IPI)) are insufficient, particularly in identifying
patients with poor prognosis who might benefit from alternative treatments.
Methods: We investigated the prognostic value of somatic mutations in DLBCL in a clinical trial (NCT00544219)
patient cohort homogenously treated with six cycles of rituximab, cyclophosphamide, hydroxydaunorubicin,
vincristine, and prednisone (R-CHOP), followed by two cycles of R (R-CHOP-14). The primary endpoint was event-
free survival (EFS) at 2 years. Secondary endpoints included progression-free survival (PFS) and overall survival (OS).
Targeted high-throughput sequencing (HTS) of tumor genomic DNA was performed on all exons or hotspots of 68
genes frequently mutated in B cell lymphomas. Mutational data was correlated with the endpoints to identify
prognostic associations.
Results: Targeted HTS detected somatic mutations in 71/76 (93%) of investigated cases. The most frequently
mutated genes were KMT2D, SOCS1, GNA13, and B2M. Survival analysis revealed that CREBBP- and EP300-mutated
cases had significantly worse OS, PFS, and EFS. In addition, ATM mutations predicted worse outcomes for all three
clinical endpoints in germinal center B cell-like DLBCL. In contrast, SOCS1 mutations were associated with better
PFS. On multivariable analysis taken into account IPI and failure to achieve complete remission, CREBBP and EP300
mutations remained significant to predict worse OS, PFS, and EFS.
Conclusion: Targeted mutation analysis of a uniformly treated prospective clinical trial DLBCL cohort identifies
tumor-based genetic prognostic markers that could be useful in the clinical management of such patients.
Trial registration: ClinicalTrials.gov NCT00544219
Keywords: DLBCL, Prognostic markers, Targeted high-throughput sequencing, NGS, Lymphoma, CREBBP, SOCS1, EP300
* Correspondence: alexandar.tzankov@usb.ch
1Institute of Pathology, University of Basel and University Hospital Basel,
Schoenbeinstrasse 40, CH-4031 Basel, Switzerland
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Juskevicius et al. Journal of Hematology & Oncology  (2017) 10:70 
DOI 10.1186/s13045-017-0438-7
Introduction
Diffuse large B cell lymphoma (DLBCL) is a heteroge-
neous and aggressive lymphoid neoplasm, the treatment
of which has significantly improved in the last decade with
addition of the anti-CD20 monoclonal antibody rituximab
(R) to the chemotherapy regimen consisting of cyclophos-
phamide, hydroxydaunorubicin, vincristine, and prednis-
one (R-CHOP) [1]. Since then, R-CHOP has become a
standard treatment for the vast majority of primary
DLBCL cases with cure rates at about 60%. The remaining
40% of DLBCL either relapses after a period of remission
or are refractory to the applied first-line therapy. Patients
in this group are treated with aggressive salvage regimens
supported by autologous stem cell transplantation (ASCT)
[2], but success rates are modest, particularly in primary
refractory DLBCL [3, 4]. Therefore, it is important to
identify high-risk patients before administration of first-
line therapy so that the potentially more aggressive tumors
can be treated with alternative regimens [5].
Risk stratification of DLBCL has relied for more than
20 years on the International Prognostic Index (IPI), which
is based on evaluation of multiple clinical parameters [6].
Following the addition of rituximab, IPI was revised (R-IPI)
[7] and, most recently, further enhanced (NCCN-IPI), to
better identify high-risk patients [8]. According to NCCN-
IPI, the high-risk group has 5-year overall survival (OS)
probability of 33% compared to 54% predicted by IPI, al-
though this remains to be confirmed by the datasets of
prospective trials.
In addition to patient-based factors, tumor-based prog-
nostic markers have been proposed. It is known that ~10%
of DLBCL cases have MYC rearrangements that are
strongly associated with worse outcomes, especially if
linked to MYC protein overexpression [9]. It has also been
shown that the activated B cell (ABC) cell-of-origin (COO)
DLBCL subtype has a worse outcome compared to the
germinal center B cell (GCB) subtype [10]. Because ori-
ginal classification based on gene expression profiling
on a transcriptome level proved to be technically too
challenging for implementation in clinical practice, sur-
rogate immunohistochemistry-based algorithms were
developed [11]. However, their utility was limited by
suboptimal concordance to the gene expression-based
gold standard. Recently, a Lymph2Cx assay, which can
measure expression of 20 genes and can be also applied
on formalin-fixed paraffin-embedded (FFPE) material,
was proposed for reproducible classification of DLBCL
into COO subgroups [12]. It remains to be seen if this
new technology will be widely accepted in lymphoma
centers worldwide. In addition to COO classification,
immunohistochemical (IHC) studies have identified
multiple protein markers, such as CD5, Ki-67, FOXP1,
HLA-I, p21, and CD40, that prospectively showed
prognostic value for R-CHOP-treated DLBCL [13–17].
During the last decade, substantial progress has been
made toward understanding the genetic basis of DLBCL
[18–20]. Shared and COO subtype-specific DNA lesions
have been identified, converging into several most fre-
quently dysregulated cellular pathways [21]. Based on
these findings, a handful of molecular prognostic markers
have been identified, among which, TP53, FOXP1, and
MYD88 mutations and CDKN2A deletions were associ-
ated with inferior outcomes in R-CHOP-treated DLBCL
[22–24]. The prognostic role of such molecular markers is
likely to increase in the near future as high-throughput se-
quencing (HTS) enters routine practice in many institu-
tions. However, more studies, particularly prospective
analyses, are required to validate the existing molecular
prognostic markers and to discover new ones that would
add power to the existing prognostication algorithms.
In this study, we employed targeted HTS to identify
somatic mutations in tumors of a well-documented pro-
spective clinical cohort consisting of uniformly treated
primary DLBCL patients. By correlating gene mutation
status to the robust survival data, we aimed to dis-




The clinical trial SAKK 38/07 (NCT00544219), active
between 2007 and 2010, included 138 eligible patients
with primary untreated DLBCL to prospectively deter-
mine the prognostic value of interim PET/CT scans by
standardized treatment and evaluation criteria. The main
clinical results have been published previously [25].
Tissue specimens of patients who consented for add-
itional translational research were used for a subsequent
study investigating the prognostic value of phenotypic
and genotypic profiles by IHC and fluorescence in situ
hybridization (FISH), the results of which have been re-
cently published in this journal [13].
For the current study, FFPE tissues of 84 primary un-
treated de novo DLBCL patients with adequate amounts
of remaining material were selected. Tumor content was
determined by morphological evaluation and was at least
50% in all samples.
Updated clinical data (last follow-up on 31 January
2017) were used for evaluation of the prognostic role of
genetic mutations. All patients in the study cohort were
uniformly treated with six cycles of R-CHOP, followed
by two cycles of R (R-CHOP-14). The primary endpoint
was event-free survival (EFS) at 2 years (for definition,
see the “Statistical analysis” section), and the secondary
endpoints were progression-free survival (PFS) and OS
at 2 and 5 years as well as objective responses according
to international criteria [26].
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DNA extraction and quantification
Genomic DNA was extracted with the GeneRead DNA
FFPE kit (Qiagen, Nussloch, Germany) following manu-
facturers’ recommendations with minor modifications.
Briefly, one to three 10–25 μm thick tissue sections were
deparaffinized by several xylene washes, rehydrated and
digested with proteinase K overnight at 56 °C in a shak-
ing heat block. Following digestion, the samples were in-
cubated for 1 h at 90 °C to reverse fixation-induced
DNA crosslinks and inactivate proteinase K. Thereafter,
uracil-N-glycosylase (UNG) enzyme was added to re-
move artificially (formalin) induced uracils and reduce
the number of false-positive C > T transitions. After in-
cubation at 37 °C for 1 h, the samples were loaded into a
DNA purification column and were washed and eluted
in 40 μl of nuclease-free water. DNA yields were quanti-
fied with the Qubit High sensitivity DNA assay (Life
Technologies, Eugene, OR, USA).
Targeted HTS sequencing variant calling and filtering
A target enrichment panel was designed to cover muta-
tional hotspots or all exons of genes most frequently
mutated in B cell lymphoid neoplasms according to the
COSMIC database (release v70) and manual review of
the literature [27]. Sequencing libraries were constructed
exactly as described previously [27]. One microliter of the
prepared library was used for the Bioanalyzer High Sensi-
tivity DNA assay (Agilent, USA) to confirm expected
DNA fragment length distribution. Quantification was
performed with the Ion Library Quantitation kit (Thermo
Fisher Scientific, Carlsbad, CA, USA) following the ori-
ginal protocol. Libraries were diluted to 40 pM, loaded to
the Ion540 sequencing chips by automated IonChef in-
strument, and sequenced with the Ion Torrent S5 XL ma-
chine (Thermo Fisher Scientific, Carlsbad, CA, USA). The
depth of coverage, coverage uniformity, and number of
variants called per sample are summarized in Additional
file 1: Table S1. Mutation identification was performed by
the Variant caller plug-in v5.0 of the Torrent Suite
(Thermo Fisher Scientific) using default low stringency
parameters for somatic mutation calling. Mutations were
annotated using the Ion Reporter variant annotation
workflow v5.0 and dbNSFP v3.0 database [28]. MetaLR
rank score was used to predict the functional impact of
non-synonymous point mutations to the encoded protein
[29]. After annotation, the variants were subjected to add-
itional, more stringent, and quality- and relevance-based
filtering by criteria as detailed in Table 1. All variants
with variant allelic frequency >5% were used in down-
stream analysis.
Finally, aligned BAM files were manually inspected at
sites of all remaining variants to exclude false-positive
mutations or other artifacts introduced during library
preparation [30].
Statistical analysis
All statistical analyses were performed using the Statistical
Package of Social Sciences (IBM SPSS version 22.0, Chicago,
IL, USA) for Windows. EFS was calculated from registration
to progressive disease or relapse, death of any cause, and ini-
tiation of any non-protocol anti-cancer treatment because of
lymphoma symptoms or need of concomitant radiotherapy.
PFS was calculated from registration to progressive disease
or relapse, and death of any cause. OS was calculated from
registration to death. Patients not experiencing an event
were censored at last follow-up. The survival probabilities
were determined using the Kaplan–Meier method, and
groups were compared using the log-rank test. Factors of
prognostic significance in univariable models underwent
multivariable analysis using the Cox proportional hazards
model. For other endpoints, differences between groups
were tested either with t test, Wilcoxon rank-sum test, or
Fisher’s exact test, as appropriate. In all tests, p values are
two-sided, considered significant if <0.05, and not cor-
rected for multiple testing. For survival analysis within the
COO subgroups, p values were corrected for multiple
testing and were considered significant if <0.017.
Results
Patients and clinico–pathologic characteristics
In total, 84 patient samples were included. Four samples
yielded insufficient DNA for HTS library preparation, and
another four samples failed quality control after sequen-
cing (low coverage uniformity, low percentage of reads
mapped to target), leaving 76 cases for further study. Pa-
tient characteristics are presented in Table 2. Survival data
was available for all 76 patients. The 2-year OS, PFS, and
EFS of the entire cohort were 91% (95% CI 84 to 98%),
Table 1 Criteria used for mutation filtering (variant inclusion)








Variant allelic frequency ≥5%
Localization Exonic and splice site
Variant effect Non-synonymous
SNP exclusion
Variant allelic frequency <95%
Database annotation and alternative
allelic frequency (1000 genomes project,
European descendent samples)
Not listed in dbSNP v138 or
listed, but MAF ≤0.01%
Variants in detected in the control
cohort of 23 non-tumoral samples from
lymphoma patients
Not overlapping
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78% (95% CI 68 to 88%), and 63% (95% CI 53 to 75%), re-
spectively. There was no significant difference in any of
the survival endpoints between the two different immuno-
histochemically determined COO subtypes. IHC and FISH
data on all samples were collected as part of the previous
translational study focusing on the prognostic value of
genotypic and phenotypic characteristics [13]. “Double-hit
score,” representing IHC-based evaluation of tumor cell
expression of BCL2 and MYC (Table 2), showed that 10/
76 (13%) cases were positive for both MYC and BCL2.
None of the investigated cases had chromosomal translo-
cations affecting both MYC and BCL2 genes. Thirty of 76
(39%) and 1/76(1%) of cases were positive for FOXP1 and
CD5, respectively, both associated with worse DLBCL out-
comes in our previous study [13]. All investigated cases
were Epstein–Barr virus (EBV)-negative as determined by
in situ hybridization for EBV early RNA (EBER).
Mutational data
In total, 317 somatic alterations were detected. Missense
mutations were the most frequent, 232/317 (73%), followed
by 40 (13%) nonsense mutations and 37 (12%) frame-
shift insertions/deletions (Fig. 1a–b and Additional
file 1: Table S2). Sixty-eight percent (46/68) of the in-
vestigated genes were mutated at least once, and at
least one somatic mutation was identified in 71/76
(93%) of investigated tumor samples. The most fre-
quently mutated gene was KMT2D (34% of cases),
followed by cytokine signaling 1 (SOCS1) (28%), GNA13
(17%), and B2M (15%) (Fig. 1c). EZH2 (p = 0.0176) along
with GNA13 (p = 0.0181) and SGK1 (p = 0.028) were more
frequently mutated in GCB–DLBCL. On average, GCB–
DLBCL cases had more mutated genes than ABC-DLBCL
cases (mean 3.9 vs 2.8, p = 0.018). However, there was no
significant difference between COO subtypes considering
the cumulative number of mutations per case (some genes
had multiple mutations in the same tumor).
We used the ensemble MetaLR score that integrates
nine different functional prediction algorithms and popu-
lation allele frequencies to predict the functional impact
of the detected missense mutations. Ninety-eight percent
of all missense mutations were successfully annotated, and
86/227 (38%) were reliably predicted to be deleterious.
Functional effects did not distribute evenly among investi-
gated genes. In some (GNA13, TP53, CREBBP, TNFAIP),
all or nearly all substitutions were either nonsense or pre-
dicted damaging missense mutations, whereas in others
(PIM1, BCL2), the majority of mutations were “neutral,”
and thus likely played a passenger role in lymphomagene-
sis (Fig. 2).
Survival analysis
We performed Kaplan–Meier survival analysis of all
genes that were mutated in at least 4 cases within our
cohort and, also, on combinations of mutated genes that
act on the same pathway. Only significant findings are
reported.
SOCS1 mutated cases had better PFS compared to
wild-type cases (p = 0.022), but the difference was not
significant for OS and EFS (p = 0.11 and p = 0.182, re-
spectively) (Fig. 3a). In total, 47 mutations of SOCS1
were detected, affecting 21 cases (12 non-GCB and 9
GCB). Mutations were distributed evenly along the cod-
ing sequence with two hotspots at Ala17 and Phe79
(four and three mutations, respectively) (Additional file
2: Figure S1). In all but 2 cases, at least one truncating
(frameshift insertion/deletion or nonsense) or predicted
damaging missense mutation was present, suggesting a
deleterious effect on protein synthesis and/or function.
Nineteen of 47 (40%) SOCS1 mutations were potentially
induced by aberrant somatic hypermutation (aSHM), as
they occurred within the RGYW/WRCY DNA sequence
motif known to be targeted by activation-induced
deaminase.
Table 2 Patient characteristics
Age, median (range) 59 (18–81)
Gender, N (%) F 34 (45)
M 42 (55)









Treatment response according to





Survival, median (IQR) PFS 55.05(56.7)
EFS 55.05 (56.7)
OS 61.9 (9.65)
Cell-of-origin (Tally) [11], N (%) non-GCB 44 (58)
GCB 32 (42)
Double-hit score, N (%) 0 35 (46)
1 31 (41)
2 10 (13)
Translocations N (%) MYC 5 (9)
BCL2 6 (11)
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Since CREBBP and EP300 have close functional inter-
actions in acetylating histone and nonhistone proteins,
we decided to evaluate their combined prognostic value.
Cases with mutations in CREBBP or EP300 had signifi-
cantly worse OS, EFS, and PFS (p = 0.0015, p = 0.005,
and p = 0.017, respectively) (Fig. 3b–d). In total, 14 cases
were affected, with one heterozygous mutation in each
case. All detected variants were missense substitutions
localized in the acetyltransferase HAT domain with pre-
dicted deleterious effects on protein function (Additional
file 2: Figure S1). However, the existence of more muta-
tions cannot be excluded, since the applied gene panel
only partly investigated the coding sequence of both
CREBBP and EP300. CREBBP mutations alone had a
negative impact on OS, but this did not reach statistical
significance (p = 0.061). Analysis of potential linkage of
these mutations to aSHM showed no such evidence.
In our previous study, we reported that overexpression of
FOXP1 evaluated by IHC was prognostic of worse OS [13].
We combined mutation- and IHC-based prognostic
markers to determine whether this improved identification
of DLBCL cases with poor outcomes. Fifty-one percent
(39/76) of cases overexpressed FOXP1 and/or had muta-
tions of CREBBP/EP300. Five tumors shared both of these
features. Survival analysis showed significantly worse OS,
PFS, and EFS in cases with either FOXP1 overexpression
or CREBBP or EP300 mutations (p = 0.0003, p = 0.006,
and p = 0.0002, respectively) (Fig. 3e–f ).
ATM mutations emerged as prognostic factor for worse
EFS, PFS, and OS within the GCB–DLBCL subgroup (p =
0.000002, p = 0.00041, and p = 0.0065, respectively;
Fig. 3g–i). In total, 11 mutations affecting 10 DLBCL cases
were found (5 in GCB and 5 in non-GCB instances). Only
in one case ATM mutations were reliably predicted to be
deleterious, while the functional significance of other mu-
tations remained unclear. Also, there was no evidence of
targeting of this gene by aberrant somatic hypermutation
as only 2/11 mutations occurred within the RGYW motif.
In multivariable analysis that included IPI and failure
to achieve complete remission (FACR), CREBBP and
EP300 mutational status (but not SOCS1 status)
emerged as the most significant factor predicting worse
Fig. 1 Overview of detected mutations. a Classification of the detected mutations according to their type. b Frequency of different nucleotide
substitutions among all types of point mutations (n = 270). c Frequency of gene mutations in respect to cell-of-origin classification
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OS (p = 0.013, HR 4.12, CI 1.38–14.15) (Table 3). While
these mutations were also significant for predicting
worse EFS and PFS (p = 0.021 and p = 0.041, respectively),
FACR was a superior predictor of the latter two end-
points (p = 0.0006 and p = 0.001).
Discussion
There is a critical need for additional tumor-based prog-
nostic markers in DLBCL to identify high-risk DLBCL
patients prior to first treatment that might benefit from
alternative risk-adjusted therapies. Tumor mutations
represent promising candidates for outcome prognosti-
cation due to the unequivocal nature of results obtained
by respective mutational detection techniques and the
increased availability and robustness of HTS. We have
demonstrated that targeted mutational analysis of a
relatively small but uniformly treated and prospectively
followed up patient cohort can reveal significant prog-
nostic associations in DLBCL. This was only possible (a
lesson learned) because of the proper trial design con-
templating central collection of tissue for translational
analysis as an integral study part. Additional lessons
learned from this prospective trial such as the import-
ance of a central diagnostic pathology review as well as
handling of biological entities and subentities in the
spectrum of so-called high grade B cell lymphomas
have been discussed in a paper of ours recently pub-
lished in this journal [13].
We found that deleterious mutations in two acetyl-
transferase genes, CREBBP and EP300, which belong to
the KAT3 family of histone/protein lysine acetyltransfer-
ases, predict worse OS, PFS, and EFS in DLBCL
Fig. 2 Overview of detected mutations and clinical endpoints. In the upper part of the figure, the occurrence of an event for each clinical endpoint is
indicated by a filled-in square. In the lower part, mutations are color-coded by their type. Additionally, missense mutations are color-coded according to their
predicted impact on protein function (MetaLR rank score, see the “Methods” section) Genes (in rows) are grouped according to their involvement in the
cellular pathway and ordered according to their mutation frequencies within each group. Cases are ordered according to the cell-of-origin subtype. If
multiple mutations occurred within one gene in the same case, the most damaging mutation is shown. COO cell-of-origin, EFS event-free survival, GCB
germinal center B cell type, OS overall survival, PFS progression-free survival
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independent of IPI and FACR. Point mutations or dele-
tions of CREBBP/EP300 reportedly affect 39% of all
DLBCL cases [31]. In line with other studies, we confirm
that CREBBP mutations are more frequent than EP300
and tend to occur more often in GCB–DLBCL [18]. In
the context of cancerogenesis, CREBBP and EP300 act
as tumor suppressors. It has been shown that loss of one
CREBBP allele leads to reduced acetylation and inactiva-
tion of p53, impaired expression of glucocorticoid-
receptor-responsive genes, and upregulation of BCL6
[31, 32]. Finally, recent data suggest that heterozygous
deleterious CREBBP mutations lead to decreased global
histone H3 lysine 14 (H3K14), K18, and K27 acetylation
and reduced MHC class II expression (Hashwah et al.,
currently under peer review). Association with poorer
outcomes were suggested in studies that found CREBBP
mutations in 20% of relapsed/refractory GCB–DLBCL
[33], and in a large proportion of relapsed acute
Fig. 3 Survival analysis according to mutational status. a Progression-free survival (PFS) in SOCS1-mutated and non-mutated cases. b–d Comparison of
overall survival (OS), PFS, and event-free survival (EFS) in CREBBP- or EP300-mutated and wild-type cases. e–f Separation between cases with good and
bad prognosis was further increased by combining CREBBP or EP300 mutational status and FOXP1 protein overexpression. g–i Prognostic significance
of ATM mutations in GCB–DLBCL
Table 3 Stepwise Cox regression analysis of survival
OS EFS PFS
Variable p value HR (95% CI) p value HR (95% CI) p value HR (95% CI)
CREBBPmut or EP300mut 0.013 4.41 (1.38–14.16) 0.021 2.53 (1.15–5.54) 0.041 2.94 (1.05–8.27)
Failure to achieve complete remission 0.032 0.27 (0.08–0.89) 0.0006 0.22 (0.097–0.53) 0.001 0.17 (0.056–0.49)
International Prognostic Index (IPI) 0.86 0.96 (0.61–1.51) 0.38 0.88 (0.66–1.17) 0.646 1.09 (0.75–1.60)
Juskevicius et al. Journal of Hematology & Oncology  (2017) 10:70 Page 7 of 10
lymphoblastic leukemia patients [31, 34]. Despite this
important clue, however, the prognostic value of
CREBBP/EP300 mutations in DLBCL has not been
previously reported.
SOCS1 mutations predicted excellent PFS in our co-
hort, but differences in OS and EFS were not significant.
Suppressor of cytokine signaling 1 (SOCS1) is a known
inhibitor of JAK/STAT-dependent signal transduction,
which binds to phosphorylated JAK and marks it for
proteosomal degradation [35, 36]. Mutations of SOCS1
have been previously shown to be associated with favor-
able survival in DLBCL [37] and are also frequently de-
tected in Hodgkin lymphoma and primary mediastinal B
cell lymphoma (PMBCL), both with a relatively favorable
prognosis [38]. We also previously showed that SOCS1
mutations occurred exceptionally in non-relapsing primary
DLBCL whereas being completely absent in relapsing
DLBCL cases, supporting the association with favorable
prognosis [27]. Schif et al. reported that DLBCL bearing
truncating SOCS1 mutations have excellent OS, whereas
those with only missense mutations have markedly worse
prognosis [37]. Our data, however, does not confirm such
distinction: 6 of 19 SOCS1-mutated cases had only mis-
sense mutations, but their PFS was equally favorable as
those with truncating mutations. The SOCS1 mutational
frequency in our cohort (28%) was higher than reported
average (~13%) [39]. All detected mutations had relatively
high variant allelic frequencies (median 28%, range 6–
78%); therefore, our higher mutation rate cannot be ex-
plained by comparably high sequencing depth and sensitive
detection of subclonal mutations that could have been
missed by exome-scale sequencing studies. A potential ex-
planation might be bias of our cohort toward better than
average survival, e.g., due to study protocol exclusion of pa-
tients with performance status >2 on the ECOG scale, with
symptomatic central nervous system disease, or with HIV,
and/or hepatitis infection, thus being potentially enriched
for cases with better prognosis that consequently more
often bear SOCS1 mutations.
The prognostic value of multiple other gene mutations
such as TP53, MYD88, FOXP1, and FOXP2 in DLBCL has
been suggested previously [22, 23, 40, 41]. In our cohort,
TP53-mutated cases had worse OS, but this difference did
not reach statistical significance. Also, the low number (n =
5) of MYD88 L265P-mutated cases did not allow detection
of any reliable prognostic associations. Analogously, despite
ATM mutations were consistently associated with worse
outcomes in GCB–DLBCL in our study, this observation
was based on a small number of events and cases bearing
mutations and therefore remains to be validated on other
larger collectives. While we were unable to identify muta-
tions of FOXP1, we previously reported that overexpres-
sion of the FOXP1 protein is associated with worse OS
in the investigated DLBCL cohort [13]. Here, we show
that combination of HTS- and IHC-based prognostic
markers (CREBBP/EP300 mutations and FOXP1 over-
expression) enables even better stratification between
patients with good and worse prognosis.
It is unlikely that any single biomarker will significantly
improve risk stratification in DLBCL due to the profound
heterogeneity of this disease. This point is illustrated by 3
cases in our cohort with mutations of both SOCS1 and
CREBBP (Fig. 2, cases UPN57, UPN112, and UPN115) that
clinically behaved like CREBBP-mutated cases and had
worse prognosis. It is more likely that a combination of sev-
eral different types of markers established on uniformly
treated prospective cohorts and selected by robust statistical
methods would provide models that could be prospectively
validated on larger DLBCL collections. A good example of
such an updated composite prognostic model is the m7-
FLIPI, a recently developed score for follicular lymph-
oma, which incorporates mutations and clinical factors
and provides superior prognostication compared to
traditionally used clinical factor-based FLIPI [42].
Conclusion
Deleterious mutations in the HAT domain of the acetyl-
transferases CREBBP and EP300 are associated with worse
OS, PFS, and EFS in DLBCL. ATM mutations are prog-
nostic for worse survival at all clinical endpoints in GCB–
DLBCL, but due to low case number remains to be veri-
fied on larger collectives. The previously reported benefi-
cial prognostic role of SOCS1 mutations in DLBCL is
valid for predicting better PFS.
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